Generic name |
filgrastim |
|
---|---|---|
Brand name |
Strength |
Form |
Grastofil® |
300 mcg/0.5 mL |
pre-filled syringe |
Nivestym® |
300 mcg/0.5 mL |
pre-filled syringe |
300 mcg/1 mL |
single-use vial |
|
Nypozi® |
300 mcg/0.5 mL |
pre-filled syringe |
Special Authority criteria |
Approval period |
---|---|
For primary prophylaxis of febrile neutropenia in cancer patients receiving potentially curative myelosuppressive chemotherapy regimens where the risk of febrile neutropenia is ≥ 20% |
6 months |
For secondary prophylaxis of febrile neutropenia in cancer patients receiving potentially curative myelosuppressive chemotherapy |
6 months |
For the rescue of prolonged febrile neutropenia following chemotherapy |
6 months |
For cancer patients undergoing peripheral blood progenitor cell collection and therapy |
6 months |
For post-bone-marrow transplant patients to stimulate bone marrow engraftment (start greater than or equal to d+1) |
6 months |
For post-bone-marrow transplant patients requiring rescue of failure to engraft (start greater than or equal to d+14) |
6 months |
For patients with the following benign disorders:
|
6 months |